News

One Nucleus Employer of Choice Collaboration with the Future of Work Institute

In May 2022, we were honored to announce our collaboration with the Future of Work Institute (FOWI) to enhance our Employer of Choice webinar series to provide our members with real world insights, guidance, and best practices on becoming employers of choice to attract and develop their best team.


Fast forward five months and we have learnt how to; become a destination workplace, support our employees and colleagues through wellbeing strategies, overcome the challenges around hybrid working and finally, to become a great storyteller.

Read more

Office spaces for rent in Cambridge

Discounted offer will be specified.


Read more

Domainex expands Executive and Management Teams to support ongoing growth

Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to announce that it has made a number of strategic internal promotions to strengthen its Executive and Management teams. This expansion marks a period of ongoing growth for Domainex, and the newly bolstered teams will be pivotal in driving further development of the company.

Read more

Babraham Research Campus Ltd appoints Kathryn Chapman as Director of Science & Entrepreneurship





Cambridge, UK, 21st November 2022:  Babraham Research Campus Ltd, which is responsible for the development and management of the Babraham Research Campus is delighted to announce the appointment of Dr Kathryn Chapman to the newly created role of Director, Science & Entrepreneurship.

Read more

ARECOR ANNOUNCES EXCLUSIVE SPECIALTY HOSPITAL FORMULATION COLLABORATION

Cambridge, UK, 10 November 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with the pharmaceutical division of one of the world’s largest chemicals marketing and pharmaceuticals companies, which focuses on the development and commercialisation of speciality drugs.

Read more

Boyds bolsters regulatory affairs team with key appointment

Leading global drug development consultancy Boyds has appointed experienced regulatory affairs professional and cell and gene therapy expert Dr Patrick Ginty.


With 17 years’ R&D and regulatory affairs experience in regenerative medicine and cell and gene therapy products, Patrick joins Boyds as Senior Director of Regulatory Affairs.

Read more

Domainex expands Executive and Management Teams to support ongoing growth

Cambridge, UK, 15th November 2022 / Sciad Newswire / Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to announce that it has made a number of strategic internal promotions to strengthen its Executive and Management teams. This expansion marks a period of ongoing growth for Domainex, and the newly bolstered teams will be pivotal in driving further development of the company.

Read more

Leaf Expression Systems and John Innes Centre Launch Collaboration on Disease Resistant Crops

A collaboration to improve disease resistance in major crops through bioengineered proteins


Norwich, UK – 14 November 2022 – Leaf Expression Systems (Leaf), a contract research and development organisation that produces high value proteins and biomolecules using its innovative plant-based expression system today announced a collaboration with the John Innes Centre.

Read more

London BioScience Innovation Centre (LBIC) announces expansion

London BioScience Innovation Centre to be first occupier at Tribeca, London


The London BioScience Innovation Centre (“LBIC”) will open a new 37,127 sq. ft. state-of-the-art innovation centre at The Apex, one of five mixed-use buildings within the ‘Tribeca’ development in the heart of King’s Cross being delivered by Reef Group and Blackrock Alternatives, through its Real Estate business.

Read more

Fast creation of custom cell lines

Traditionally creating optimized, stable cell lines has been a time-consuming and complex process. Drawing upon proprietary technology - AMSBIO can deliver the high-quality cell lines you need with a single customer-defined knock-in in just 25% of the time required with conventional approaches.


Using a patented FAST-HDR plasmid vector system – AMSBIO can dramatically speed vector construction and reduce the time required to successfully isolate modified clones following transfection.

Read more

Pages